 |
|
How Safe Is Long-term Prenatal Glucocorticoid Treatment?
Jonathan R. Seckl, PhD, FRCPE;
Walter L. Miller, MD
JAMA. 1997;277(13):1077-1079.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
GLUCOCORTICOIDS are commonly used in obstetric practice, both for maternal immunosuppression and for shortterm treatment of the fetus, usually to accelerate lung maturation when there is threatened preterm delivery. The immediate benefits of short-term prepartum glucocorticoid therapy in maturing the fetal lung and reducing neonatal mortality are clearly supported by controlled studies.1,2 Recently, long-term prenatal therapy of fetuses potentially affected with congenital adrenal hyperplasia (CAH) has been advocated,3,4 but the safety of this experimental therapy has not been established in rigorously controlled trials.
See also p 1073.
Congenital adrenal hyperplasia is a recessively inherited disease in which a disordered steroidogenic enzyme, usually P450c21 (21-hydroxylase), diverts adrenal steroid synthesis away from cortisol toward androgens.5 In utero, low fetal plasma cortisol levels stimulate increased corticotropin (ACTH) secretion, which in turn stimulates further adrenal steroidogenesis, resulting in even more androgen synthesis. In an XY male fetus, these adrenal androgens have
. . . [Full Text PDF of this Article]
Author Affiliations
From the Molecular Medicine Centre, University of Edinburgh, Western General Hospital, Edinburgh, Scotland (Dr Seckl), and the Department of Pediatrics, University of California, San Francisco (Dr Miller).
Footnotes
Reprints: Walter L. Miller, MD, Bldg MR-IV, Room 209, University of California, San Francisco, San Francisco, CA 94143-0978.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
